Leadman(SZ:300289) Xin Lang Cai Jing·2025-10-21 06:35Core Viewpoint - Lidman has shown a significant stock price increase of 57.14% year-to-date, indicating strong market performance despite recent fluctuations [2]. Financial Performance - As of September 30, Lidman reported a revenue of 1.60 billion yuan for the first half of 2025, reflecting a year-on-year decrease of 14.80%. The net profit attributable to shareholders was -4.25 million yuan, a decline of 800.43% compared to the previous year [3]. - The company has distributed a total of 1.43 billion yuan in dividends since its A-share listing, with 5.44 million yuan distributed over the last three years [4]. Stock Market Activity - On October 21, Lidman's stock price rose by 2.12%, reaching 7.70 yuan per share, with a trading volume of 87.37 million yuan and a turnover rate of 2.12%. The total market capitalization stood at 4.189 billion yuan [1]. - The stock has appeared on the "龙虎榜" (Dragon and Tiger List) four times this year, with the most recent appearance on August 8 [3]. Shareholder Information - As of September 30, the number of shareholders for Lidman was 32,900, a decrease of 1.79% from the previous period. The average number of circulating shares per shareholder increased by 1.82% to 16,487 shares [3]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 424,900 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 2.2007 million shares [4]. Business Overview - Lidman, established on November 5, 1997, and listed on February 16, 2012, specializes in in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials. The revenue composition is as follows: 67.84% from in vitro diagnostic reagents, 14.17% from diagnostic instruments, 13.21% from other services (such as property management), and 4.78% from biochemical raw materials [3]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and in vitro diagnostic sectors, with involvement in gene sequencing, assisted reproduction, and precision medicine [3].